Phase I/II study of two different schedules of bortezomib (Velcade, PS-341) and pemetrexed (Alimta) in advanced solid tumors, with emphasis on non-small cell lung cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Bortezomib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2007 Status change from suspended to completed.
- 24 Nov 2006 New trial record.